Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Latest Advancements in Biotech Consultancy Services: What You Need to Know

Jun 28, 2026By Sreejith Kanhirangadan

SK

Introduction to Biotech Consultancy

Biotech consultancy services have become essential for companies navigating the complex landscape of biotechnology. As the industry evolves, these consultants offer vital expertise and guidance, ensuring companies remain competitive and compliant. Understanding the latest advancements in this field can give businesses a significant edge.

biotech laboratory

Precision Medicine and Personalized Solutions

One of the most exciting advancements in biotech consultancy is the focus on precision medicine. Consultants are now helping companies develop personalized solutions tailored to individual genetic profiles. This shift not only enhances treatment efficacy but also reduces side effects, offering a more patient-centric approach.

Consultants employ cutting-edge technologies, such as genomic sequencing and bioinformatics, to provide insights that were previously unattainable. These technologies enable the development of targeted therapies, revolutionizing the way diseases are treated and managed.

Regulatory Expertise and Compliance

Navigating the regulatory landscape is a major challenge for biotech companies. Recent advancements in biotech consultancy include enhanced regulatory expertise, ensuring that companies meet stringent compliance requirements. Consultants work closely with regulatory bodies, helping businesses understand and adhere to complex regulations.

regulatory compliance

By staying abreast of changes in legislation and guidelines, biotech consultants help companies avoid costly delays and ensure smooth market entry. Their expertise is crucial in an industry where compliance is not just a requirement but a pathway to success.

Data-Driven Decision Making

Data analytics has become a cornerstone of biotech consultancy. The ability to analyze large datasets allows consultants to provide actionable insights that drive decision-making. These insights enable companies to optimize their operations, streamline research, and improve overall efficiency.

  • Predictive analytics for market trends
  • Optimization of research and development processes
  • Enhanced patient outcomes through data-driven strategies
data analysis

Collaborative Innovation

Collaboration is key to innovation in the biotech sector. Consultants are increasingly facilitating partnerships between companies, research institutions, and technology providers. This collaborative approach accelerates innovation, allowing for the rapid development and commercialization of new technologies.

Consultants also play a significant role in fostering cross-border collaborations, opening up new markets and opportunities for growth. By bridging gaps between different stakeholders, they ensure that innovation is not limited by geographical boundaries.

The Future of Biotech Consultancy

As the biotech industry continues to evolve, consultancy services will play an even more critical role. The integration of artificial intelligence, machine learning, and other emerging technologies promises to further enhance the capabilities of consultants.

Staying informed about these advancements is crucial for any company looking to succeed in the biotech sector. By leveraging the expertise of biotech consultants, businesses can navigate challenges, seize opportunities, and drive innovation in this dynamic field.